CureVac ditches first generation Covid vaccine to focus efforts on variant jab

It said in a statement it was withdrawing its current vaccine candidate – CVnCoV – from EMA approval after it estimated that it would not be approved until spring 2022

(PA)

CureVac has dropped its first version of a Covid-19 vaccine as it shifts its focus to its “second generation” jab.

The German pharmaceutical company’s vaccine candidate was going through a rolling review with the Europeans Medicines Agency (EMA), but has pulled out from the process.